NEW BRUNSWICK, N.J. (
Johnson & Johnson
is in advanced talks to buy
, the Dutch biotech company.
J&J, which already owns 17.9% of Crucell, would acquire the rest of Crucell for €1.75 billion ($2.3 billion), or €24.75 a share, in cash.
Crucell closed Thursday at €15.70, making the intended offer a 58% premium.
Crucell is a maker of vaccines and sells a line of cells widely used as a platform for developing vaccines.
The boards of J&J and Crucell have authorized the companies to proceed with the talks for a potential transaction.
The companies expect that Crucell's strength in the manufacturing, discovery and commercialization of vaccines would create a strong platform for J&J in vaccines, the companies said in a statement Friday.
-- Written by Joseph Woelfel
>To contact the writer of this article, click here:
>To submit a news tip, send an email to:
Copyright 2010 TheStreet.com Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. AP contributed to this report.